Frédérique Penault-Llorca

发表

Data Mining Used To Characterize Discordance In Gastric Cancers HER2 Status Determination To Help For A Better Treatment Decision

D Pau, Geneviève Monges, Laurent Doucet, 2016 .

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

Borivoj Vojnovic, Dejan Juric, Charles M. Perou, 2014, Science Signaling.

Promising pre-clinical validation of targeted radionuclide therapy using a [131I] labelled iodoquinoxaline derivative for an effective melanoma treatment

Frédérique Penault-Llorca, F. Penault-Llorca, N. Moins, 2009 .

DNA repair genes implicated in triple negative familial non-BRCA1/2 breast cancer predisposition.

Fabrice Kwiatkowski, Frédérique Penault-Llorca, F. Penault-Llorca, 2015, American journal of cancer research.

The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer.

Pietro Panizza, Laura Martincich, Nadia Harbeck, 2012, European journal of cancer.

High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study.

Anne Vincent-Salomon, Magali Lacroix-Triki, Marie-Christine Mathieu, 2006, European journal of cancer.

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Mitch Dowsett, Frédérique Penault-Llorca, M. Dowsett, 2014, Modern Pathology.

An international Ki67 reproducibility study.

John M S Bartlett, Mitch Dowsett, Lisa M McShane, 2013, Journal of the National Cancer Institute.

[Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines].

Frédérique Penault-Llorca, F. Penault-Llorca, J. Sabourin, 2002, Annales de pathologie.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Sabine Tejpar, Federico Cappuzzo, Mauro Delorenzi, 2010, The Lancet. Oncology.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases

Jean-Marc Guinebretière, Gaëtan MacGrogan, Sophie Krieger, 2013, BMC Cancer.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?

Frédérique Penault-Llorca, F. Penault-Llorca, N. Radosevic-Robin, 2015, Critical reviews in oncology/hematology.

A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers

Alain Viari, Thomas Bachelot, Michael R. Stratton, 2016, Nature Communications.

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

Manfred Dietel, Gustavo Baretton, Axel Walch, 2010, Virchows Archiv.

Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy

Sabine Tejpar, Bruno Landi, Simona Rossi, 2014, Clinical Cancer Research.

HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

Philippe Broët, Anne Vincent-Salomon, Jérôme Couturier, 2007, PloS one.